Trial Profile

A Canadian open-label study to evaluate the safety and effectiveness of adalimumab when added to inadequate therapy for the treatment of psoriatic arthritis (PsA) (ACCLAIM)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications Psoriatic arthritis
Focus Therapeutic Use
Acronyms ACCLAIM
Sponsors Abbott Laboratories

Most Recent Events

17 Jun 2017 Results of post-hoc analysis data from two studies (ACCLAIM and ADEPT) presented at the 18th Annual Congress of the European League Against Rheumatism
03 May 2008 Status changed from in progress to completed
20 Feb 2007 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com